Exhibit 99.1
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Keryx to Host Investor Conference Call on Tuesday, November 10, 2009
at 8:30am EST
NEW YORK, November 9, 2009 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the “Company”), today announced its results for the third quarter ended September 30, 2009.
At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million which were paid subsequent to September 30, 2009.
The net income for the third quarter ended September 30, 2009, was $0.6 million, or $0.01 per diluted share, compared to a net loss of $6.8 million, or $0.15 per diluted share, for the third quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement, a $1.4 million decrease in other selling, general and administrative expenses, and a $1.4 million decrease in non-cash compensation expense related to equity grants.
The net income for the nine months ended September 30, 2009, was $15.1 million, or $0.31 per diluted share, compared to a net loss of $49.1 million, or $1.11 per diluted share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $5.4 million decrease in research and development expenses related to KRX-0401 (perifosine), a $20.8 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) which eliminated the Company’s significant ongoing obligations included in the original agreement ($18.0 million) and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009, and a $3.6 million increase in other revenue primarily related to the settlement of a dispute for $3.5 million (as discussed above).
Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made substantial progress in the third quarter. Following our announcements of an SPA for the Phase 3 trial of perifosine in multiple myeloma, and exciting long-term safety and efficacy data for Zerenex, we solidified our balance sheet with a $20 million registered direct offering.” Mr. Bentsur added, “We believe we now have sufficient capital to complete the Phase 3 programs for Perifosine and Zerenex, both of which are nearing commencement.”
On Tuesday, November 10, 2009, at 8:30am EST, the Company will host an investor conference call during which they will provide a brief overview of the Company’s third quarter financial results and a business outlook for the remainder of 2009.
In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in our pipeline, including KRX-0401 and Zerenex; or the effect on our stock value of the other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
Source: Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc.
Selected Consolidated Financial Data
(In Thousands, Except Share and Per Share Amounts)
Statements of Operations Information: |
| | | Three Months Ended September 30, (unaudited) | | | Nine Months Ended September 30, (unaudited) | |
| | | 2009 | | | 2008 | | | 2009 | | | 2008 | |
| | | | | | | | | | | | | |
| REVENUE: | | | | | | | | | | | | |
| License revenue | | $ | -- | | | $ | 327 | | | $ | 21,616 | | | $ | 853 | |
| Service revenue | | | -- | | | | 41 | | | | 3 | | | | 103 | |
| Other revenue | | | 3,500 | | | | -- | | | | 3,575 | | | | -- | |
| TOTAL REVENUE | | | 3,500 | | | | 368 | | | | 25,194 | | | | 956 | |
| | | | | | | | | | | | | | | | | |
| OPERATING EXPENSES: | | | | | | | | | | | | | | | | |
| Cost of services | | | -- | | | | 13 | | | | -- | | | | 27 | |
| | | | | | | | | | | | | | | | | |
| Research and development: | | | | | | | | | | | | | | | | |
| Non-cash compensation | | | 388 | | | | 334 | | | | 950 | | | | (395 | ) |
| Other research and development | | | 1,527 | | | | 2,208 | | | | 4,357 | | | | 37,277 | |
| Total research and development | | | 1,915 | | | | 2,542 | | | | 5,307 | | | | 36,882 | |
| | | | | | | | | | | | | | | | | |
| Selling, general and administrative: | | | | | | | | | | | | | | | | |
| Non-cash compensation | | | 250 | | | | 1,662 | | | | 1,648 | | | | 5,146 | |
| Other selling, general and administrative | | | 904 | | | | 2,284 | | | | 3,473 | | | | 6,249 | |
| Total selling, general and administrative | | | 1,154 | | | | 3,946 | | | | 5,121 | | | | 11,395 | |
| | | | | | | | | | | | | | | | | |
| TOTAL OPERATING EXPENSES | | | 3,069 | | | | 6,501 | | | | 10,428 | | | | 48,304 | |
| | | | | | | | | | | | | | | | | |
| OPERATING INCOME (LOSS) | | | 431 | | | | (6,133 | ) | | | 14,766 | | | | (47,348 | ) |
| | | | | | | | | | | | | | | | | |
| OTHER INCOME (EXPENSE): | | | | | | | | | | | | | | | | |
| Interest and other income (expense), net | | | 129 | | | | (622 | ) | | | 377 | | | | (1,551 | ) |
| | | | | | | | | | | | | | | | | |
| INCOME (LOSS) FROM CONTINUING OPERATIONS | | | 560 | | | | (6,755 | ) | | | 15,143 | | | | (48,899 | ) |
| Loss from discontinued operations | | | -- | | | | (86 | ) | | | -- | | | | (175 | ) |
| | | | | | | | | | | | | | | | | |
| NET INCOME (LOSS) | | $ | 560 | | | $ | (6,841 | ) | | $ | 15,143 | | | $ | (49,074 | ) |
| | | | | | | | | | | | | | | | | |
| NET INCOME (LOSS) PER COMMON SHARE | | | | | | | | | | | | | | | | |
Basic | | $ | 0.01 | | | $ | (0.15 | ) | | $ | 0.32 | | | $ | (1.11 | ) |
| | | | | | | | | | | | | | | | | |
| Diluted | | $ | 0.01 | | | $ | (0.15 | ) | | $ | 0.31 | | | $ | (1.11 | ) |
| | | | | | | | | | | | | | | | | |
| SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE | | | | | | | | | | | | | | | | |
Basic | | | 47,932,029 | | | | 45,222,053 | | | | 47,880,737 | | | | 44,348,537 | |
| | | | | | | | | | | | | | | | | |
| Diluted | | | 49,028,254 | | | | 45,222,053 | | | | 48,326,718 | | | | 44,348,537 | |
Balance Sheet Information:
| | | September 30, 2009 | | | December 31, 2008* | |
| | | (unaudited) | | | | |
| Cash, cash equivalents, interest receivable | | | | | | |
| and short-term investment securities | | $ | 33,687 | | | $ | 15,467 | |
| Long-term investment securities | | | 7,333 | | | | 7,185 | |
| Total assets | | | 45,458 | | | | 26,634 | |
| Accumulated deficit | | | (316,775 | ) | | | (331,918 | ) |
| Stockholders’ equity (deficiency) | | | 34,959 | | | | (1,489 | ) |
* Condensed from audited financial statements.
